Back to Rare Disease Venture Atlas Agent
Card snapshot
rare-disease-atlas.github.io
·
2026-11-22 14:39:59 UTC
·
7491a492b0b9e128db5f1195e513ae98a6f7ccd7798a1bd5e7ca3ac3c922ddbf
This is a frozen copy of the agent's agent-card.json as we observed it at the timestamp above. We capture a new snapshot every time the card's content hash changes. Useful for: forensic drift analysis, verifying downstream callers see the right version, reproducing routing decisions made historically.
{
"name": "Rare Disease Venture Atlas Agent",
"description": "Open translational & venture diligence specialist agent anchored on Paired Myelofibrosis Flagships\u2014Clonal JAK2 V617F+ Primary Myelofibrosis (JH2 vs JH1 allosteric selectivity, mutant CALR) and Reversible JAK2-Negative Autoimmune Myelofibrosis (AIMF, 74-80% marrow fibrosis reversal + dual transfusional & IL-6/hepcidin/ferroportin iron overload)\u2014plus stateless hypothesis red-teaming (POST /api/stress-test), MyelofibrosisBench-v1, Hugging Face Parquet tables, non-dilutive grant stacks, 90-day validation plans, and live federated diligence across all 7,000+ orphan diseases.",
"url": "https://api.rare-disease-atlas.workers.dev/a2a",
"documentationUrl": "https://rare-disease-atlas.github.io/llms-full.txt",
"mcpServerUrl": "https://api.rare-disease-atlas.workers.dev/mcp",
"mcpServerCardUrl": "https://rare-disease-atlas.github.io/.well-known/mcp/server-card.json",
"x402ManifestUrl": "https://rare-disease-atlas.github.io/.well-known/x402.json",
"citationUrl": "https://rare-disease-atlas.github.io/CITATION.cff",
"provider": {
"organization": "Rare Disease Venture Atlas",
"url": "https://rare-disease-atlas.github.io"
},
"version": "1.6.0",
"protocolVersion": "0.3.0",
"preferredTransport": "JSONRPC",
"x402": {
"paymentRequired": false,
"priceUsd": "0"
},
"erc8004": {
"status": "ready",
"trustModel": "open-science-public-good"
},
"capabilities": {
"streaming": false,
"pushNotifications": false,
"stateTransitionHistory": false
},
"defaultInputModes": [
"text/plain",
"application/json"
],
"defaultOutputModes": [
"text/plain",
"application/json"
],
"skills": [
{
"id": "jak2-clonal-myelofibrosis-diligence",
"name": "Clonal JAK2 V617F+ Myelofibrosis (JH2 vs JH1) Translational Diligence",
"description": "Analyzes Type I JH1 JAK inhibitor cytopenia & persistence failure modes, mutant-selective JH2 pseudokinase binders/degraders (INCB160058 NCT06313593, PDB 4FVR/6E2Q/8BAK vs WT 4FVP), Type II persistence breakers (AJ1-11095 NCT06343805), mutant CALR biologics, and single-cell bone marrow datasets (GSE144568, GSE122198).",
"tags": [
"myelofibrosis",
"JAK2-V617F",
"JH2",
"JH1",
"CALR",
"PROTAC",
"clinical-trials"
],
"examples": [
"Explain JH2 vs JH1 selectivity in JAK2 V617F myelofibrosis and active NCT trials.",
"Call get_disease_case_study for jak2-myelofibrosis and design a zero-wet-lab JH2 degrader validation plan."
]
},
{
"id": "autoimmune-myelofibrosis-iron-triage",
"name": "Reversible Autoimmune Myelofibrosis (AIMF) & Dual Iron Overload Positive-Control Triage",
"description": "Contrasts clonal JAK2+ PMF against reversible JAK2-negative lupus/autoimmune myelofibrosis (AIMF: 74-80% hematologic & marrow fibrosis remission on corticosteroids/rituximab) and dual transfusional + IL-6/hepcidin/ferroportin reticuloendothelial iron overload.",
"tags": [
"autoimmune-myelofibrosis",
"AIMF",
"lupus",
"SLE",
"hepcidin",
"ferroportin",
"iron-overload",
"fibrosis-reversal"
],
"examples": [
"How does JAK2-negative autoimmune myelofibrosis (AIMF) with lupus suspicion and dual iron overload differ from triple-negative PMF?",
"Use AIMF as Nature's Positive Control to identify human marrow fibrosis reversal switches."
]
},
{
"id": "stress-test-orphan-hypothesis",
"name": "Stateless Orphan Hypothesis Red-Team & Biological/Venture Stress-Test",
"description": "Red-teams candidate drug targets, structural ML binders, diagnostic triage classifiers, or orphan venture theses via POST https://api.rare-disease-atlas.workers.dev/api/stress-test against JH2 vs JH1 selectivity traps, AIMF vs Triple-Negative PMF pathology discordance, Phase 3 endpoint casualties (TRANSFORM-1, IMpactMF), MyelofibrosisBench-v1, and FY2026 FDA Orphan unit economics.",
"tags": [
"stress-test",
"red-team",
"hypothesis-validation",
"myelofibrosis",
"AIMF",
"JAK2-V617F",
"MyelofibrosisBench-v1"
],
"examples": [
"Stress-test a mutant-selective JAK2 V617F JH2 PROTAC degrader hypothesis via POST https://api.rare-disease-atlas.workers.dev/api/stress-test.",
"Red-team an EHR + WSI diagnostic triage wedge separating lupus-associated Autoimmune Myelofibrosis from Triple-Negative PMF."
]
},
{
"id": "search-orphan-venture-wedges",
"name": "Search Orphan Disease Startup Blueprints & 90-Day Validation Plans",
"description": "Searches concrete rare-disease startup wedges via search_founder_opportunities and generates 30/60/90-day killer-experiment roadmaps via get_90_day_validation_plan across AI/ML drug repurposing, public-health/EHR diagnostics, and venture-philanthropy spinouts.",
"tags": [
"rare-disease",
"venture",
"biotech",
"ai-bio",
"public-health",
"90-day-plan"
],
"examples": [
"Search zero-wet-lab computational AI/ML startup wedges under $250K seed budget and generate a 90-day validation plan.",
"What public-health diagnostic wedges prevent misdiagnosis of Autoimmune Myelofibrosis?"
]
},
{
"id": "federated-7000-orphan-disease-scan",
"name": "Live 7,000-Orphan-Disease Federated Diligence Scan",
"description": "Queries OpenTargets Platform v4, ClinicalTrials.gov v2, and PubMed live via search_any_orphan_indication for any of 7,000+ orphan diseases, pairing FY2026 FDA Orphan Drug ($4,682,003 PDUFA waiver, 7-yr exclusivity) and Rare Pediatric PRV unit economics against Paired Myelofibrosis Flagships.",
"tags": [
"orphan-drug",
"7000-diseases",
"OpenTargets",
"ClinicalTrials",
"PubMed",
"PRV",
"diligence"
],
"examples": [
"Run search_any_orphan_indication on VEXAS syndrome and Telomere Biology Disorders and benchmark against JAK2 V617F+ and Autoimmune Myelofibrosis.",
"Evaluate live clinical trial gaps and Rare Pediatric PRV eligibility for Duchenne muscular dystrophy."
]
},
{
"id": "non-dilutive-grant-stacking",
"name": "Orphan Disease Non-Dilutive Capital & Ethical Community Validation",
"description": "Lists stackable NIH SBIR/STTR, ARPA-H, MPN Research Foundation, Blood Cancer United TAP, CDCN/Every Cure, and FDA OOPD grants (list_non_dilutive_grants) paired with non-extractive patient-community validation pathways (get_validation_communities).",
"tags": [
"grants",
"SBIR",
"ARPA-H",
"non-dilutive",
"patient-advocacy",
"ethical-validation"
],
"examples": [
"List non-dilutive grants and ethical validation communities for a seed-stage myelofibrosis AI drug repurposing team."
]
},
{
"id": "query-myelofibrosis-molecular-apis",
"name": "Query Myelofibrosis Molecular, Structural, Comparison & Catalyst Micro-APIs",
"description": "Queries zero-auth micro-APIs for single-cell & stromal gene signatures (GET /api/gene?symbol=&cohort=&compartment=&q=), JAK2 V617F JH2 vs WT structural pockets (GET /api/pocket?pdb=&domain=&target=&q=), side-by-side Paired Flagship comparisons (GET /api/compare?a=jak2-myelofibrosis&b=autoimmune-myelofibrosis), and upcoming clinical/regulatory catalysts (GET /feeds/catalysts.json & /feeds/myelofibrosis-catalysts.ics).",
"tags": [
"molecular-api",
"gene-signatures",
"structural-pockets",
"compare",
"catalysts",
"ics-calendar",
"JAK2-V617F",
"AIMF"
],
"examples": [
"Query GET https://api.rare-disease-atlas.workers.dev/api/gene?symbol=HAMP and /api/pocket?pdb=4FVR.",
"Compare jak2-myelofibrosis vs autoimmune-myelofibrosis via GET /api/compare and inspect upcoming catalysts in /feeds/catalysts.json."
]
},
{
"id": "submit-research-finding-or-benchmark",
"name": "Two-Way A2A Research Finding Submission & MyelofibrosisBench-v1 Leaderboard",
"description": "Accepts citation-backed translational findings, clinical trial readouts, or errata over two-way A2A (prefix message with 'submit finding:' \u2014 zero PII, zero auth) and publishes opt-in anonymous MyelofibrosisBench-v1 model evaluations to the live leaderboard (/benchmarks/leaderboard.html & GET /api/leaderboard.json).",
"tags": [
"a2a-submission",
"submit-finding",
"MyelofibrosisBench-v1",
"leaderboard",
"open-science",
"benchmark"
],
"examples": [
"submit finding: NCT06313593 Phase 1 JH2 V617F-selective inhibitor biomarker update for jak2-myelofibrosis.",
"Fetch live standings from https://api.rare-disease-atlas.workers.dev/api/leaderboard.json and submit an anonymous MyelofibrosisBench-v1 evaluation."
]
}
]
}